Results 61 to 70 of about 47,434 (363)

Evaluating the Utility of ctDNA in Detecting Residual Cancer and Predicting Recurrence in Patients with Serous Ovarian Cancer

International Journal of Molecular Sciences, 2023
Ovarian cancer has a high case fatality rate, but patients who have no visible residual disease after surgery have a relatively good prognosis. The presence of any cancer cells left in the peritoneal cavity after treatment may precipitate a cancer ...
Jiezhi Zhu, F. Wong, Agata Szymiczek, G. Ene, Shiyu Zhang, T. May, S. Narod, J. Kotsopoulos, M. Akbari   +8 more
semanticscholar   +1 more source

New Frontiers in Diagnosis and Therapy of Circulating Tumor Markers in Cerebrospinal Fluid In Vitro and In Vivo

Cells, 2019
One of the greatest challenges in neuro-oncology is diagnosis and therapy (theranostics) of leptomeningeal metastasis (LM), brain metastasis (BM) and brain tumors (BT), which are associated with poor prognosis in patients.
Olga A. Sindeeva, Roman A. Verkhovskii, Mustafa Sarimollaoglu, Galina A. Afanaseva, Alexander S. Fedonnikov, Evgeny Yu. Osintsev, Elena N. Kurochkina, Dmitry A. Gorin, Sergey M. Deyev, Vladimir P. Zharov, Ekaterina I. Galanzha   +10 more
doaj   +1 more source

Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy. [PDF]

, 2018
BACKGROUND:We report the successful treatment of the patient with osimertinib 80 mg/day following disease progression and a discordance in the detection of a mechanism of resistance epithelial growth factor receptor (EGFR) T790 M between liquid biopsy ...
Mambetsariev, Isa, Salgia, Ravi, Vora, Lalit, Yu, Kim Wai   +3 more
core   +1 more source

ctDNA-based molecular residual disease and survival in resectable colorectal cancer

Nature Network Boston
The interim analysis of the CIRCULATE-Japan GALAXY observational study demonstrated the association of circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) detection with recurrence risk and benefit from adjuvant chemotherapy (ACT) in ...
Y. Nakamura, J. Watanabe, N. Akazawa, K. Hirata, K. Kataoka, Mitsuru Yokota, Ken Kato, M. Kotaka, Y. Kagawa, Kun-Huei Yeh, S. Mishima, H. Yukami, K. Ando, M. Miyo, Toshihiro Misumi, Kentaro Yamazaki, Hiromichi Ebi, K. Okita, Atsushi Hamabe, Hiroki Sokuoka, Satoshi Kobayashi, G. Laliotis, Vasily N. Aushev, Shruti Sharma, A. Jurdi, Minetta C. Liu, A. Aleshin, M. Rabinowitz, H. Bando, H. Taniguchi, I. Takemasa, T. Kato, D. Kotani, Masaki Mori, T. Yoshino, E. Oki   +35 more
semanticscholar   +1 more source

Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer

Clinical Cancer Research, 2023
Purpose: Circulating tumor DNA (ctDNA) has emerged as a promising tumor-specific biomarker in pancreatic cancer, but current evidence of the clinical potential of ctDNA is limited. In this study, we used comprehensive detection methodology to explore the
Morten Lapin, Karin H Edland, Kjersti Tjensvoll, Satu Oltedal, Marie Austdal, H. Garresori, Y. Rozenholc, Bjørnar Gilje, Oddmund Nordgård   +8 more
semanticscholar   +1 more source

Molecular clustering on ctDNA improves the prognostic stratification of patients with DLBCL compared with ctDNA levels

Blood Advances
Abstract Circulating tumor DNA (ctDNA) levels can help predict outcomes in diffuse large B-cell lymphoma (DLBCL), but its integration with DLBCL molecular clusters remains unexplored. Using the LymphGen tool in 77 DLBCL cases with both ctDNA and tissue biopsy, a 95.8% concordance rate in molecular cluster assignment
Riccardo Moia, Donatella Talotta, Lodovico Terzi Di Bergamo, Mohammad Almasri, Riccardo Dondolin, Matin Salehi, Chiara Cosentino, Roberta Soscia, Irene Della Starza, Alessio Bruscaggin, Annalisa Andorno, Francesca Mercalli, Stefania Cresta, Riccardo Bomben, Tamara Bittolo, Filippo Vit, Pietro Bulian, Antonella Zucchetto, Riccardo Bruna, Giulia Maria Rivolta, Mattia Schipani, Eleonora Secomandi, Sreekar Kogila, Matteo Bellia, Samir Mouhssine, Jana Nabki, Bashar Al Deeban, Joseph Ghanej, Luca Cividini, Nawar Maher, Federica Melle, Giovanna Motta, Monica Leutner, Angela Lorenzi, Abdurraouf Mokhtar Mahmoud, Wael Al Essa, Clara Deambrogi, Silvia Rasi, Luigi Petrucci, Renzo Luciano Boldorini, Alice Di Rocco, Ilaria Del Giudice, Michele Spina, Stefano Palazzolo, Fabio Canal, Vincenzo Canzonieri, Maurizio Martelli, Stefano Pileri, Valter Gattei, Robin Foà, Davide Rossi, Gianluca Gaidano   +51 more
openaire   +6 more sources

Pan-cancer screening by circulating tumor DNA (ctDNA) – recent breakthroughs and chronic pitfalls

Journal of Laboratory Medicine, 2022
Early detection is crucial for optimal treatment and prognosis of cancer. New approaches for pan-cancer screening comprise the comprehensive characterization of circulating tumor DNA (ctDNA) in plasma by next generation sequencing and molecular profiling
Holdenrieder Stefan, Ungerer Vida, Oberhofer Angela, Bronkhorst Abel Jacobus   +3 more
doaj   +1 more source

The Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer. [PDF]

, 2015
The advances in targeted therapies for lung cancer are based on the evaluation of specific gene mutations especially the epidermal growth factor receptor (EGFR).
Huang, Wei-Lun, Lin, Chien-Chung, Su, Wu-Chou, Wei, Fang, Wong, David T   +4 more
core   +2 more sources

Use of ctDNA in early breast cancer: analytical validity and clinical potential

npj Breast Cancer
Circulating free tumor DNA (ctDNA) analysis is gaining popularity in precision oncology, particularly in metastatic breast cancer, as it provides non-invasive, real-time tumor information to complement tissue biopsies, allowing for tailored treatment ...
François Panet, A. Papakonstantinou, M. Borrell, Joan Vivancos, A. Vivancos, Mafalda Oliveira   +5 more
semanticscholar   +1 more source

Plasma ctDNA TP53 Mutation and Breast Cancer Prognosis: A Systematic Review and Meta-Analysis

Xiehe Yixue Zazhi
ObjectiveTo analyze the association between plasma circulating tumor DNA (ctDNA) TP53 mutation status and survival outcomes in breast cancer patients.MethodsPubMed, Embase, and the Cochrane Library were searched for relevant literature published between ...
FAN Hao, LIANG Annan, ZOU Wei, GAO Guangxi, LIU Lijin, LIU Fei, ZHAO Lina, WU Zhihong   +7 more
doaj   +1 more source